HK1051498A1 - Use of fulvestrant in the treatment of resistant breast cancer - Google Patents

Use of fulvestrant in the treatment of resistant breast cancer

Info

Publication number: HK1051498A1
Authority: HK; Hong Kong
Prior art keywords: fulvestrant; treatment; breast cancer; resistant breast; resistant
Prior art date: 2000-04-05

Application number

HK03103770A

Other languages

English (en)

Inventor

Beat Thurlimann

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-05

Filing date

2003-05-27

Publication date

2003-08-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1051498(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-05-27 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2003-08-08 Publication of HK1051498A1 publication Critical patent/HK1051498A1/xx

Links

206010006187 Breast cancer Diseases 0.000 title abstract 2
208000026310 Breast neoplasm Diseases 0.000 title abstract 2
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title abstract 2
229960002258 fulvestrant Drugs 0.000 title abstract 2
229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 2
239000000333 selective estrogen receptor modulator Substances 0.000 abstract 2
229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
239000003886 aromatase inhibitor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HK03103770A 2000-04-05 2003-05-27 Use of fulvestrant in the treatment of resistant breast cancer HK1051498A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0008172.9A GB0008172D0 (en)	2000-04-05	2000-04-05	Therapy
PCT/GB2001/001500 WO2001074366A1 (en)	2000-04-05	2001-04-02	Use of fulvestrant in the treatment of resistant breast cancer

Publications (1)

Publication Number	Publication Date
HK1051498A1 true HK1051498A1 (en)	2003-08-08

Family

ID=9889101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK03103770A HK1051498A1 (en)	2000-04-05	2003-05-27	Use of fulvestrant in the treatment of resistant breast cancer

Country Status (29)

Country	Link
US (2)	US20030158166A1 (es)
EP (2)	EP1272195B1 (es)
JP (1)	JP2003528919A (es)
KR (1)	KR100757764B1 (es)
CN (1)	CN1431905A (es)
AT (1)	ATE306270T1 (es)
AU (2)	AU2001244372B2 (es)
BR (1)	BR0109789A (es)
CA (1)	CA2403608A1 (es)
CH (1)	CH1272195H1 (es)
CZ (1)	CZ303096B6 (es)
DE (1)	DE60113975T2 (es)
DK (1)	DK1272195T3 (es)
EE (1)	EE05026B1 (es)
ES (1)	ES2248300T3 (es)
GB (1)	GB0008172D0 (es)
HK (1)	HK1051498A1 (es)
HU (1)	HU230064B1 (es)
IL (2)	IL151932A0 (es)
IS (1)	IS2869B (es)
MX (1)	MXPA02009744A (es)
NO (1)	NO329949B1 (es)
NZ (1)	NZ539603A (es)
PL (1)	PL201175B1 (es)
RU (1)	RU2265438C2 (es)
SK (1)	SK287779B6 (es)
UA (1)	UA80388C2 (es)
WO (1)	WO2001074366A1 (es)
ZA (1)	ZA200207538B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2453111A1 (en) *	2001-07-07	2003-01-23	Alan Marshall Irving	Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0116620D0 (en) *	2001-07-07	2001-08-29	Astrazeneca Ab	Formulation
EP1623713A1 (en) *	2004-07-09	2006-02-08	Proskelia SAS	Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) *	2005-09-27	2013-10-15	Robert Benson Aylor	Suppression and prevention of tumors
JP5256042B2 (ja) *	2005-11-22	2013-08-07	インサイト・コーポレイション	癌の処置のための併用療法
WO2007143600A2 (en) *	2006-06-05	2007-12-13	Incyte Corporation	Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
MX2013013104A (es) *	2011-05-09	2014-10-15	Univ Virginia Patent Found	Composiciones y metodos para el tratamiento de cancer.
BR112013029758A2 (pt)	2011-05-20	2018-10-09	Capital, Business Y Gestion De Finanzas S.L.	composição farmacêutica
EP3092027A4 (en) *	2014-01-10	2017-09-06	Atossa Genetics Inc.	Transpapillary methods and compositions for diagnosing and treating breast conditions
WO2019051416A1 (en)	2017-09-11	2019-03-14	Atossa Genetics Inc.	METHODS FOR THE MANUFACTURE AND USE OF ENDOXIFEN
AU2019274815A1 (en) *	2018-05-24	2021-01-21	Shivanka Research LLC	Prodrugs of fulvestrant
US20230255974A1 (en) *	2020-02-29	2023-08-17	The University Of Vermont	Use of thyromimetics for the treatment of cancer

2000
- 2000-04-05 GB GBGB0008172.9A patent/GB0008172D0/en not_active Ceased
2001
- 2001-02-04 UA UA2002118734A patent/UA80388C2/uk unknown
- 2001-04-02 PL PL357936A patent/PL201175B1/pl unknown
- 2001-04-02 KR KR1020027013366A patent/KR100757764B1/ko active IP Right Grant
- 2001-04-02 JP JP2001572110A patent/JP2003528919A/ja active Pending
- 2001-04-02 ES ES01917289T patent/ES2248300T3/es not_active Expired - Lifetime
- 2001-04-02 CH CH01917289T patent/CH1272195H1/de unknown
- 2001-04-02 AU AU2001244372A patent/AU2001244372B2/en not_active Expired
- 2001-04-02 HU HU0300339A patent/HU230064B1/hu unknown
- 2001-04-02 CN CN01810539A patent/CN1431905A/zh active Pending
- 2001-04-02 DK DK01917289T patent/DK1272195T3/da active
- 2001-04-02 SK SK1429-2002A patent/SK287779B6/sk not_active IP Right Cessation
- 2001-04-02 AU AU4437201A patent/AU4437201A/xx active Pending
- 2001-04-02 MX MXPA02009744A patent/MXPA02009744A/es active IP Right Grant
- 2001-04-02 CA CA002403608A patent/CA2403608A1/en not_active Abandoned
- 2001-04-02 RU RU2002129355/14A patent/RU2265438C2/ru active
- 2001-04-02 BR BR0109789-0A patent/BR0109789A/pt not_active Application Discontinuation
- 2001-04-02 EP EP01917289A patent/EP1272195B1/en not_active Expired - Lifetime
- 2001-04-02 NZ NZ539603A patent/NZ539603A/en not_active IP Right Cessation
- 2001-04-02 IL IL15193201A patent/IL151932A0/xx active IP Right Grant
- 2001-04-02 EP EP05007561A patent/EP1586323A1/en not_active Withdrawn
- 2001-04-02 WO PCT/GB2001/001500 patent/WO2001074366A1/en active IP Right Grant
- 2001-04-02 EE EEP200200574A patent/EE05026B1/xx unknown
- 2001-04-02 DE DE60113975T patent/DE60113975T2/de not_active Expired - Lifetime
- 2001-04-02 US US10/240,656 patent/US20030158166A1/en not_active Abandoned
- 2001-04-02 CZ CZ20023309A patent/CZ303096B6/cs not_active IP Right Cessation
- 2001-04-02 AT AT01917289T patent/ATE306270T1/de active
2002
- 2002-09-19 ZA ZA200207538A patent/ZA200207538B/en unknown
- 2002-09-25 IL IL151932A patent/IL151932A/en unknown
- 2002-10-01 IS IS6576A patent/IS2869B/is unknown
- 2002-10-02 NO NO20024735A patent/NO329949B1/no not_active IP Right Cessation
2003
- 2003-05-27 HK HK03103770A patent/HK1051498A1/xx not_active IP Right Cessation
2010
- 2010-09-30 US US12/895,369 patent/US20110183949A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20030007501A (ko)	2003-01-23
JP2003528919A (ja)	2003-09-30
BR0109789A (pt)	2003-01-21
RU2265438C2 (ru)	2005-12-10
NO329949B1 (no)	2011-01-31
IL151932A0 (en)	2003-04-10
GB0008172D0 (en)	2000-05-24
NO20024735D0 (no)	2002-10-02
CA2403608A1 (en)	2001-10-11
HUP0300339A2 (hu)	2003-06-28
KR100757764B1 (ko)	2007-09-12
ZA200207538B (en)	2003-12-19
IL151932A (en)	2007-07-04
NO20024735L (no)	2002-11-27
UA80388C2 (en)	2007-09-25
PL357936A1 (en)	2004-08-09
EE05026B1 (et)	2008-06-16
DE60113975D1 (de)	2006-02-23
ES2248300T3 (es)	2006-03-16
HU230064B1 (hu)	2015-06-29
EE200200574A (et)	2004-04-15
US20110183949A1 (en)	2011-07-28
CH1272195H1 (es)	2019-10-15
EP1272195B1 (en)	2005-10-12
DK1272195T3 (da)	2006-01-16
NZ539603A (en)	2008-02-29
ATE306270T1 (de)	2005-10-15
EP1586323A1 (en)	2005-10-19
CZ303096B6 (cs)	2012-04-04
SK287779B6 (sk)	2011-09-05
EP1272195A1 (en)	2003-01-08
AU4437201A (en)	2001-10-15
IS2869B (is)	2014-03-15
DE60113975T2 (de)	2006-06-22
IS6576A (is)	2002-10-01
HUP0300339A3 (en)	2009-01-28
WO2001074366A1 (en)	2001-10-11
AU2001244372B2 (en)	2006-02-16
MXPA02009744A (es)	2004-02-26
CZ20023309A3 (cs)	2003-02-12
US20030158166A1 (en)	2003-08-21
CN1431905A (zh)	2003-07-23
SK14292002A3 (sk)	2003-08-05
PL201175B1 (pl)	2009-03-31

Legal Events

Date	Code	Title	Description
2021-04-16	PE	Patent expired	Effective date: 20210401

Publication	Publication Date	Title
HUS1500001I1 (hu)	2016-08-29	ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére
ATE430570T1 (de)	2009-05-15	Synergistische kombinationstherapie zur krebsbehandlung
EP1355563A4 (en)	2004-07-21	METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
IL164599A0 (en)	2005-12-18	Combination therapy for the treatment of cancer
EP1077704A4 (en)	2002-01-30	COMBINATION THERAPY FOR TREATING DEPRESSION
IL151932A0 (en)	2003-04-10	Use of fulvestrant in the treatment of resistant breast cancer
IL159887A0 (en)	2004-06-20	Combination therapy for the treatment of cancer
MXPA04003674A (es)	2004-07-23	Uso mejorado de compuesto antitumoral en terapia de cancer.
EP1383573A4 (en)	2005-09-14	METHOD AND DEVICE FOR THE TREATMENT OF ANGRYED TISSUE
MY138883A (en)	2009-08-28	Use of asiatic acid for treatment of cencer
MXPA03008582A (es)	2003-12-08	Agentes y metodos para tratamiento de cancer.
IL158206A0 (en)	2004-05-12	Compositions and methods for the prevention and treatment of human prostate cancer
HK1043058A1 (zh)	2002-09-06	異環磷酰胺芥子類似物及其用途
AU2003250912A8 (en)	2004-01-23	Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
AU2002366195A8 (en)	2003-06-10	Use of bisindolmaleimide and gemcitabine for the treatment of cancer
EP1409734A4 (en)	2005-10-19	DIAGNOSIS AND TREATMENT OF CANCER
EP1684795A4 (en)	2009-07-29	METHODS AND AGENTS FOR THE TREATMENT OF CANCER
IL149705A0 (en)	2002-11-10	Combination treatment for depression and anxiety
SI1272195T1 (sl)	2006-02-28	Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk
GB9826603D0 (en)	1999-01-27	Device for treatment, especially putting in plaster, of patients limb
UA28113C2 (uk)	2000-10-16	Спосіб експрес-тестування ефективності реабілітації здоров'я людини
GB0115943D0 (en)	2001-08-22	Treatment and diagosis of cancer
AU2002313029A1 (en)	2002-11-18	Apparatus for skin stimulation and treatment